The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Th2‐mediated anti‐tumour immunity: friend or foe?
Open accessAbstract
The concept that the immune system can recognise tumour cells and either eliminate them (tumour immune surveillance) or select for immunologically resistant variants (immunoediting) is gaining general acceptance by immunologists. In terms of an adaptive immune response to cancer, however, much of the research has focused on the response of cytotoxic CD8+ T lymphocytes to tumour‐specific antigens and the production of Th1 cytokines by CD4+ and CD8+ T cells. In contrast, Th2‐mediated immunity has traditionally been viewed as favouring tumour growth, both by promoting angiogenesis and by inhibiting cell‐mediated immunity and subsequent tumour cell killing. While there is evidence that components of type 2 inflammation, such as B cells and interleukin‐10, do promote tumour growth, there are also many studies demonstrating the anti‐tumour activity of CD4+ Th2 cells, particularly in collaboration with tumour‐infiltrating granulocytes, such as eosinophils. In this review, we examine all the components of type 2 immunity and their effects on tumour growth. Collectively, from this analysis, we conclude that there is a great potential for the development of Th2‐mediated immunotherapies that harness the cytotoxic activity of eosinophils.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345
Cancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324
Rodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0465 · Cited by 1,276
Anthony, R. M., Urban, J. F., Alem, F., Hamed, H. A., Rozo, C. T., Boucher, J.-L., Van Rooijen, N., & Gause, W. C. (2006) · Nature Medicine · doi:10.1038/nm1451 · Cited by 522
Primary Antitumor Immune Response Mediated by CD4+ T Cells
Corthay, A., Skovseth, D. K., Lundin, K. U., Røsjø, E., Omholt, H., Hofgaard, P. O., Haraldsen, G., & Bogen, B. (2005) · Immunity · doi:10.1016/j.immuni.2005.02.003 · Cited by 478
Cited by
Stromal gene expression predicts clinical outcome in breast cancer
Finak, G., Bertos, N., Pepin, F., Sadekova, S., Souleimanova, M., Zhao, H., Chen, H., Omeroglu, G., Meterissian, S., Omeroglu, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1764 · Cited by 1,687
Brain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium
Bondy, M. L., Scheurer, M. E., Malmer, B., Barnholtz-Sloan, J. S., Davis, F. G., Il'yasova, D., Kruchko, C., McCarthy, B. J., Rajaraman, P., Schwartzbaum, J. A., et al. (2008) · Cancer · doi:10.1002/cncr.23741 · Cited by 932
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Labani-Motlagh, A., Ashja-Mahdavi, M., & Loskog, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00940 · Cited by 751
Anisakis simplex: from Obscure Infectious Worm to Inducer of Immune Hypersensitivity
Audicana, M. T., & Kennedy, M. W. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00012-07 · Cited by 581
Speiser, D. E., Chijioke, O., Schaeuble, K., & Münz, C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00521-2 · Cited by 479
Metadata
- Authors
- Ellyard, J. I., Simson, L., & Parish, C. R.
- Venue
- Tissue Antigens
- Publisher
- Wiley
- Published
- 2007-06-06
- Volume
- 70
- Issue
- 1
- Pages
- 1-11
- ISSN
- 0001-2815 (ISSN-L)
- 1399-0039
- OpenAlex
- W2081272311
- Cited by
- 207
- References
- 6
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Th2‐mediated anti‐tumour immunity: friend or foe? https://app.cochat.ai/papers/10.1111/j.1399-0039.2007.00869.x
- The paper
- Ellyard, J. I., Simson, L., & Parish, C. R. (2007). Th2‐mediated anti‐tumour immunity: friend or foe? Tissue Antigens. https://doi.org/10.1111/j.1399-0039.2007.00869.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.